We are proud to share that Marengo will be presenting during the Clinical Plenary Oral Session at the upcoming AACR Annual Meeting – Marengo Therapeutics
Marengo Therapeutics shared a post on LinkedIn:
“We are proud to share that Marengo will be presenting during the Clinical Plenary Oral Session at the upcoming American Association for Cancer Research (AACR) Annual Meeting!
We look forward to sharing updated clinical results from our STARt-001 trial studying Invikafusp alfa as a monotherapy in PD1 resistant tumors.
Read the full press release here.
Stay tuned for more details – we hope to see you in Chicago next month!”
Shiva Bolourchi, Executive Director, Head of Corporate Strategy and Partnerships at Marengo Therapeutics, shared a post by Marengo Therapeutics on LinkedIn, adding:
“3.5+ years into this incredible journey with the Marengo team, and we’re beginning to see our novel T cell agonists translate into clinical impact for patients.
It’s truly an honor to have our work selected for an oral presentation at this year’s AACR. Grateful for the opportunity to share what we’ve been building – and to be part of this exciting moment for IO.
Hope to see many of you in Chicago! Send me a message if you would like to set up time to meet.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023